目的 探討達(dá)格列凈聯(lián)合二甲雙胍對(duì)2型糖尿病的臨床治療效果。方法 選取2016年1月-2017年6月西安市第一醫(yī)院收治的2型糖尿病患者97例，按治療方法分為對(duì)照組48例、觀(guān)察組49例。所有患者均給予1個(gè)月的導(dǎo)入治療，結(jié)束后對(duì)照組使用二甲雙胍治療，觀(guān)察組在此基礎(chǔ)上聯(lián)合達(dá)格列凈治療。兩組均連續(xù)治療3個(gè)月，每2周對(duì)患者進(jìn)行一次電話(huà)隨訪(fǎng)，每1個(gè)月對(duì)患者進(jìn)行一次門(mén)診隨訪(fǎng)。比較兩組治療前后血糖、血流動(dòng)力學(xué)相關(guān)指標(biāo)的變化，比較兩組治療期間不良反應(yīng)的發(fā)生情況。結(jié)果 兩組治療前空腹血糖（FBG）、糖化血紅蛋白（HbA1c）、餐后2 h血糖（2hPG）間無(wú)顯著差異，治療后兩組以上指標(biāo)均顯著降低（P<0.05），且觀(guān)察組顯著低于對(duì)照組（P<0.05）。兩組治療前視網(wǎng)膜中央動(dòng)脈（CRA）、睫狀后動(dòng)脈（PCA）的收縮期峰值流速（PSV）、舒張末期血流速度（EDV）、阻力指數(shù)（RI）間無(wú)顯著差異，治療后以上指標(biāo)均顯著升高（P<0.05），且觀(guān)察組較對(duì)照組更顯著（P<0.05）。治療期間，觀(guān)察組的不良反應(yīng)發(fā)生率是18.37%，與對(duì)照組的18.75%間無(wú)顯著差異。結(jié)論 達(dá)格列凈聯(lián)合二甲雙胍對(duì)2型糖尿病的療效確切，可顯著降低FBG、HbA1c、2hPG水平，改善球后動(dòng)脈血流動(dòng)力學(xué)相關(guān)指標(biāo)，值得臨床應(yīng)用推廣。

Objective To explore the clinical efficacy of dapagliflozin combined with metfotmin on type 2 diabetes mellitus. Methods Selected 97 patients with type 2 diabetes mellitus in our hospital from January 2016 to June 2017. All patients were divided into control group (n=48) and observation group (n=49). All patients were given 1 month of induction therapy, the control group were treated with metformin after the induction therapy, the observation group were treated with dapagliflozin on the basis of control group. The blood glucose, hemodynamics and the incidence of adverse reactions were compared between two groups. Results There was no significant difference between FBG, HbA1c and 2hPG before treatment in both groups. After treatment, the above two indexes were significantly lower (P<0.05), and the observation group was more obvious than the control group (P<0.05). There were no significant differences in PSV, EDV and RI between CRA and PCA before treatment in both groups, and the above indexes were significantly increased after treatment (P<0.05), and the observation group was more significant than the control group (P<0.05). During the treatment, The incidence of adverse reactions of the observation group (18.37%) was not significantly different from that in the control group (18.75%). Conclusions Dapagliflozin combined with metformin has definite curative effect on type 2 diabetes mellitus, which can significantly reduce the levels of FBG, HbA1c and 2hPG, and improve hemodynamics of the posterior arteries related indicators, which is worthy of promotion in clinical application.